Clinical trials: Aggressive Behaviour
Drink Too Much, Drinking, Binge
Group-based Intervention for Club Patrons
The purpose of this study is to develop and test a group-based strategy for encouraging groups of young adults who are engaged in party behaviors at nightclubs to intervene with each other to reduce harms associated with overuse…
- Conditions
- Drink Too Much, Drinking, Binge, Drunk, Drug Use
- Trial name
- NCT03652688
- Testing
- Nightlife Safety Plans (NSP), Fire Safety
- Where
- 2 sites in United States
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- Pacific Institute for Research and Evaluation
Fever
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Fever, defined as temperature higher than 38.3C (100.9 F), is common in patients with head injuries and is associated with poor recovery after injury.
- Trial name
- NCT01530880
- Testing
- Intravenous Ibuprofen, Acetaminophen (Standard of Care)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Columbia University
Aggression, Anger
Group CBT for Aggression in Veterans
Posttraumatic stress disorder (PTSD) robustly predicts anger and aggression, and U.S. Iraq/Afghanistan-era combat Veterans report that treatment for anger and aggression is among their top priorities.
- Conditions
- Aggression, Anger, Posttraumatic Stress Disorder
- Trial name
- CBT-A (NCT02233517)
- Testing
- Cognitive Behavioral Therapy, Present Centered Therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Rheumatoid Arthritis
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment…
- Trial name
- TEAR (NCT00259610)
- Testing
- methotrexate, sulfasalazine, hydroxychloroquine
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- University of Alabama at Birmingham
Antisocial Behavior, Aggression
The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior
This study investigates the effect of upregulating prefrontal cortex activity on antisocial and aggressive behavior and risk factors for such behavior.
- Trial name
- NCT02427672
- Testing
- Transcranial direct current stimulation
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Trauma, Brain, Brain Injuries
Intervention to Change Attributions That Are Negative (ICAN)
ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial.
- Conditions
- Trauma, Brain, Brain Injuries, Traumatic Brain Injury, Brain Injuries, Traumatic
- Trial name
- ICAN (NCT03648476)
- Testing
- ICAN
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Indiana University
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Localized Aggressive Periodontitis
Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis
combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed…
- Trial name
- NCT02402296
- Testing
- β-1,3/1,6-D-glucan
- Volunteers
- 30 people
- Sponsor
- Al-Azhar University
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease, Agitation
Citalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
- Trial name
- CitAD (NCT00898807)
- Testing
- citalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- JHSPH Center for Clinical Trials
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Aggressive Periodontitis
Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis
The aim of this study is to assess the clinical outcomes of full-mouth ultrasonic debridement combined with clarithromycin or amoxicillin + metronidazole association for the treatment of generalized aggressive periodontitis…
- Trial name
- NCT02969928
- Testing
- Full-mouth ultrasonic debridement, Clarithromycin, Amoxicillin
- Where
- Brazil
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
This phase II trial studies the side effects and how well high-dose yttrium-90 (Y-90)-ibritumomab tiuxetan (anti-cluster of differentiation [CD]20) followed by fludarabine phosphate, low-dose total body irradiation (TBI), and…
- Conditions
- Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma
- Trial name
- NCT01434472
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma
Zevalin-beam for Aggressive Lymphoma
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will…
- Trial name
- NCT00491491
- Testing
- ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Evaluation of efficacy, safety profile and tolerability of rituximab (MabThera) in combination with chemotherapy in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT02486952
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin
- Where
- 5 sites in Serbia
- Volunteers
- 154 people
- Sponsor
- Hoffmann-La Roche
Pituitary Adenomas, Prolactinomas
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, and select medical therapies…
- Trial name
- NCT00939523
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cedars-Sinai Medical Center
Lymphoma
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00244985
- Testing
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute